The estimated Net Worth of Ira E. Ritter is at least $2.16 Millón dollars as of 4 March 2020. Mr. Ritter owns over 18,750 units of Ritter Pharmaceuticals stock worth over $800,925 and over the last 9 years he sold RTTR stock worth over $7,125. In addition, he makes $1,352,730 as Director at Ritter Pharmaceuticals.
Ira has made over 3 trades of the Ritter Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 18,750 units of RTTR stock worth $7,125 on 4 March 2020.
The largest trade he's ever made was selling 18,750 units of Ritter Pharmaceuticals stock on 4 March 2020 worth over $7,125. On average, Ira trades about 2,404 units every 113 days since 2015. As of 4 March 2020 he still owns at least 81,727 units of Ritter Pharmaceuticals stock.
You can see the complete history of Mr. Ritter stock trades at the bottom of the page.
Ira E. Ritter serves as Director of the Company. Mr. Ritter served as Co-Founder, Chief Strategic Officer and Executive Chairman of Ritter’s predecessor from its inception in 2004 through the formation of the Company in 2008 and he has served in those positions with the Company from 2008 until the Merger. Mr. Ritter has extensive experience creating and building diverse business enterprises and has provided corporate management, strategic planning and financial consulting for a wide range of market segments including; health product related national distribution and private label production, television and publishing. He assisted taking the Company public on Nasdaq and Martin Lawrence Art Galleries public on the New York Stock Exchange. Since 2010, Mr. Ritter has also acted as a managing partner of Stonehenge Partners, LLC. Mr. Ritter has a long history of public service that includes appointments by three Governors to several State of California Commissions including eight years as Commissioner on the California Prison Industry Authority. He has guest lectured at University of Southern California Marshall School of Business and Pepperdine University Graziadio School of Business, where he also serves as an advisory board member to Pepperdine’s Graduate School of Education and Psychology, Social Entrepreneurship and Change Program. He previously served on the boards of directors for Vitavis Laboratories and SCWorx.
As the Director of Ritter Pharmaceuticals, the total compensation of Ira Ritter at Ritter Pharmaceuticals is $1,352,730. There are no executives at Ritter Pharmaceuticals getting paid more.
Ira Ritter is 71, he's been the Director of Ritter Pharmaceuticals since 2020. There are no older and 7 younger executives at Ritter Pharmaceuticals.
Ira's mailing address filed with the SEC is RITTER PHARMACEUTICALS, INC.,, 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES,, CA, 90067.
Over the last 9 years, insiders at Ritter Pharmaceuticals have traded over $124,250 worth of Ritter Pharmaceuticals stock and bought 1,819,751 units worth $8,518,572 . The most active insiders traders include Noah Doyle, Venture Partners, L.P. Javelin y Matthew W Foehr. On average, Ritter Pharmaceuticals executives and independent directors trade stock every 86 days with the average trade being worth of $1,400,057. The most recent stock trade was executed by Noah Doyle on 12 March 2020, trading 500,000 units of RTTR stock currently worth $110,000.
Ritter Pharmaceuticals, Inc. engages in the development of novel therapeutic products which modulate the human gut microbiome to treat digestive disorders and gastrointestinal diseases. It focuses on the development and commercialization of RP-G28. The company was founded by Andrew J. Ritter and Ira E. Ritter on March 29, 2004 and is headquartered in Los Angeles, CA.
Ritter Pharmaceuticals executives and other stock owners filed with the SEC include: